Hexarelin Protects Heart Cells from Damage by Modulating Autophagy
Background
Cardiac hypertrophy, an enlargement of heart muscle cells, is a significant risk factor for heart failure and is often triggered by factors like angiotensin II. This condition involves complex cellular remodeling, and while autophagy (a cellular self-cleaning process) plays a critical role in maintaining cellular homeostasis, its precise involvement in mitigating hypertrophy, especially in response to potential therapeutic agents, is not fully understood. This study investigates whether Hexarelin protects heart cells from angiotensin II-induced hypertrophy by regulating autophagy. This mechanistic insight could pave the way for new therapeutic strategies.
Results
The study found that angiotensin II treatment significantly increased markers of hypertrophy in H9C2 cells, including a 2.5-fold increase in cell surface area and a 3-fold upregulation of ANP mRNA expression compared to untreated control cells. However, co-treatment with Hexarelin dose-dependently attenuated these hypertrophic changes, reducing cell surface area by up to 45% and ANP expression by 60% at the highest concentration tested (10 µM). Hexarelin treatment significantly restored autophagy flux, evidenced by a 1.8-fold increase in the LC3-II/LC3-I ratio and a 35% decrease in p62 protein levels compared to angiotensin II-treated cells (p<0.01), indicating enhanced cellular self-cleaning. Furthermore, Hexarelin modulated key autophagy-related proteins, preventing the angiotensin II-induced suppression of Beclin-1 and Atg7 expression, which are crucial for initiating and executing the autophagy process.
Why It Matters
This research highlights Hexarelin's potential as a therapeutic agent for preventing or treating cardiac hypertrophy, a significant contributor to heart failure and a major public health concern. By demonstrating its ability to restore cellular self-cleaning processes (autophagy) and mitigate hypertrophic remodeling, this study provides novel mechanistic insights into its cardioprotective effects. These findings suggest Hexarelin could be developed into a new drug to combat heart enlargement and improve cardiac function. Future research should focus on validating these effects in relevant in vivo animal models of cardiac hypertrophy and eventually progressing to human clinical trials to assess its safety and efficacy in a clinical setting.